Most patients with primary hyperparathyroidism have mild hypercalcemia but otherwise display no overt signs or symptoms of the disease. Greater awareness of primary hyperparathyroidism has led to the need to develop and apply technologies that can assess potential target organ involvement in otherwise asymptomatic individuals. The most important technologic advance is the bone mineral densitometer. As measured by dual-energy x-ray absorptiometery, many patients with asymptomatic primary hyperparathyroidism show substantial reductions in skeletal mass in areas that are most vulnerable to the actions of parathyroid hormone, namely cortical areas (arms and legs). Other sites such as the spine, composed mainly of cancellous bone, appear to be relatively protected from the major catabolic effects of parathyroid hormone. This assessment has helped to identify patients with asymptomatic primary hyperparathyroidism who are candidates for surgery as well as those who can be monitored safely without surgery. The 4− to 6-year course of disease in both groups of patients, those who do and those who do not undergo parathyroid surgery, is reviewed here. The results of densitometric and other indices of the hyperparathyroid state, combined with clinical outcomes, support the clinical relevance of these guidelines.